Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile
Open Access
- 29 December 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (12) , e15534
Abstract
Fibroblast growth factor 21 (FGF-21) is a metabolic regulator with multiple beneficial effects on glucose homeostasis and lipid metabolism in animal models. The relationship between plasma levels of FGF-21 and coronary heart disease (CHD) in unknown. This study aimed to investigate the correlation of serum FGF-21 levels and lipid metabolism in the patients with coronary heart disease. We performed a logistic regression analysis of the relation between serum levels of FGF-21 and CHD patients with and without diabetes and hypertension. This study was conducted in the Departments of Endocrinology and Cardiovascular Diseases at two University Hospitals. Participants consisted of one hundred and thirty-five patients who have been diagnosed to have CHD and sixty-one control subjects. Serum FGF-21 level and levels of fasting blood glucose; triglyceride; apolipoprotein B100; HOMA-IR; insulin; total cholesterol; HDL-cholesterol; LDL-cholesterol; and C-reactive protein were measured. We found that median serum FGF-21 levels were significantly higher in CHD than that of control subjects (P<0.0001). Serum FGF-21 levels in CHD patients with diabetes, hypertension, or both were higher than that of patients without these comorbidities. Serum FGF-21 levels correlated positively with triglycerides, fasting blood glucose, apolipoprotein B100, insulin and HOMA-IR but negatively with HDL-C and apolipoprotein A1 after adjusting for BMI, diabetes and hypertension. Logistic regression analysis demonstrated that FGF-21 showed an independent association with triglyceride and apolipoprotein A1. High levels of FGF-21 are associated with adverse lipid profiles in CHD patients. The paradoxical increase of serum FGF-21 in CHD patients may indicate a compensatory response or resistance to FGF-21.Keywords
This publication has 30 references indexed in Scilit:
- The FGF family: biology, pathophysiology and therapyNature Reviews Drug Discovery, 2009
- Actions and Mode of Actions of FGF19 Subfamily MembersEndocrine Journal, 2008
- FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's diseaseProceedings of the National Academy of Sciences, 2005
- FGF-21 as a novel metabolic regulatorJournal of Clinical Investigation, 2005
- Protective effects of non-mitogenic human acidic fibroblast growth factor on hydrogen peroxide-induced damage to cardiomyocytesin vitroWorld Journal of Gastroenterology, 2005
- Enhanced anti-apoptosis and gut epithelium protection function of acidic fibroblast growth factor after cancelling of its mitogenic activityWorld Journal of Gastroenterology, 2004
- Identification of a novel FGF, FGF-21, preferentially expressed in the liverBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 2000
- Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2Proceedings of the National Academy of Sciences, 1998
- Acidic fibroblast growth factor reduces renal morphologic and functional indicators of injury caused by ischemia and reperfusionWound Repair and Regeneration, 1996
- Acidic fibroblast growth factor reduces rat skeletal muscle damage caused by ischemia and reperfusion.1995